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Abstract 
 The use of compounded bioidentical hormones in the various forms of gels, creams, and 
troches has increased in popularity.  The population of menopausal women is at a crossroads 
with the cascade of symptoms and determining what are their options.  The Endocrine Society, 
the Food and Drug Administration, and the National Menopause Society do not support the use 
of bioidentical hormones, despite the support for bioidentical hormone replacement therapy 
(BHRT) by the American Academy for Anti-Aging Medicine and other proponents for BHRT.  
The literature review reveals the need for studies documenting the safety of BHRT.  The 
objective for this study was to conduct a retrospective chart review for the incidence of adverse 
outcomes specific to osteoporosis, breast cancer incidence, and cardiovascular disease in 
menopausal women utilizing BHRT. 
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Chapter 1 
Introduction 
 The use of bio-identical hormone replacement therapy (BHRT) for the alleviation of 
menopausal symptoms is being selected by women in the United States (US) (Watt, Hughes, 
Rettew, & Adams, 2003), however the research regarding BHRT is limited.  Pharmaceutical 
treatment for menopausal symptoms is a topic of debate and has received significant attention by 
women, the media, the Food and Drug Administration, and the medical field (Garber, 2008; 
North American Menopause Society (NAMS), 2010; Rosenthal, 2008; Rossouw et al., 2007). 
Since the publication of the results of the Women’s Health Initiative trial (WHI) announcing the 
increased risk for stroke, venous thrombosis, and breast cancer, and with  no favorable outcome 
on coronary heart disease (CHD), there has been an increase in alternative approaches to the 
types of hormone replacement therapy (Cirigiliano, 2007). 
In 2010, nearly 23 million women living in the United States were between the ages of 45 
and 54 (U.S. Census Bureau, 2010), while the average age for natural menopause in the United 
States is 51 (NAMS, 2013). The midlife symbolizes many lifestyle and biological changes for 
women that include the transition to menopause. It is estimated women may live approximately 
30 years following menopause (Warren & Valente, 2004). This increase in longevity from earlier 
decades thereby places the risk for age-related health conditions that affect post-menopausal 
women. The incidence of most chronic conditions such as colon cancer, cardiovascular disease, 
Alzheimer’s disease and osteoporosis increases in the post-menopausal phase of a woman’s life 
(Shoupe, 2012).   
The period of time prior to menopause is referred to as perimenopause, and during this 
stage, symptoms occur from the decrease in ovarian function and estrogen production eventually  
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ceases (Holloway, 2011), also referred to the menopausal transition time (Bastian, Smith, & 
Nanda, 2003; Meleis, Sawyer, Im, Messias, & Schumacher, 2000).  This period of transition is 
often signified as a phase of unpredictable hormone fluctuations preceding menopause (Nelson, 
2008) and the onset of fluctuations in reproductive hormones preceding natural menopause in 
women (Bastian, Smith, & Nanda,  2003).  Smoking and low-socioeconomic status are 
associated with premature final menstrual periods, as well as age at menarche, parity, previous 
oral contraceptive use, body-mass index, ethnic origin, and family history (Nelson, 2008). 
The purpose of this project was to investigate if the use of Biest and Progesterone after 
four years or longer increased the risk for: 
1. Osteoporosis. 
2. Breast cancer. 
3. Cardiovascular disease. 
Theoretical Framework 
The Transition Theory by Meleis was used to frame this project, as menopause is a period 
of time for women when they are transitioning from a stage in their life of being fertile to the 
next stage of being non-fertile (Im & Meleis, 2000).  The major concepts of Meleis’ middle 
range transition theory include: a) types and patterns of transitions; b) properties of transition 
experiences; c) transition conditions; d) process indicators; e) outcome indicators; and f) nursing 
therapeutics (Meleis, Alligood, & Tomey, 2006).  Properties within Transition theory consist of 
awareness, engagement, change and difference, time span, and critical points and events (Im & 
Meleis, 2000; Meleis, 2010), which can be applied to a woman experiencing symptoms during 
perimenopause and menopause.  
The development of the transition theory originated in the mid-1960’s, while Meleis was 
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working on her PhD, beginning the development of her theoretical journey (Im, 2013).  The 
concept of transition is associated with developmental theory and the stress adaptation theory.  
One of the important attributes of transition is that it is essentially positive.  The resolution of 
transition denotes the individual has achieved greater steadiness comparable with the pre-
transition state.  Subsequently Meleis’ research became focused on individuals unable to 
formulate healthy transitions and the unhealthy transitions or unsuccessful transitions in relation 
to role deficiency (Im, 2013). 
The sources utilized in the development of the Transition Theory included Meleis’ 
education in nursing, sociology, symbolic interactionism, and role theory.  Meleis’s initial theory 
included development of role deficiency and role supplementation in the 1970’s.  Collaboration 
with Norma Chick from Massey University, New Zealand lead to further development of the 
transition theory, resulting in the publication of Meleis’s initial article on transitions in nursing in 
1985 (Im, 2013).  Subsequently, Meleis worked with Karen Schumacher, a doctoral student at 
the University of California, San Francisco; it was during this time when an extensive literature 
search was conducted and the discovery of massive use of transition was used in the nursing 
literature (Im, 2013).  Their literature review identified 310 articles focused on transition as a 
concept in the nursing literature; Meleis subsequently further elaborated on the transition 
framework (Schumacher & Meleis, 1994).   
The defining qualities of transition include process, disconnectedness, perception, and 
patterns of response (Meleis, 2010).  The following events lead to a process of transition 
including: illness, recovery, birthing, death, loss, immigration, migration, hospitalization, 
pregnancy, retirement, and maturation (Meleis, 2010).  Therefore the use of transition theory can 
be applied to menopause in women and has been utilized in previous menopause studies as 
BIOIDENTICAL HORMONE SAFETY  8 
 
evidence by the seminal study by Im and Meleis (2000).  This study included 119 first generation 
Korean immigrant women, while Marnocha, Bergstrom, and Dempsey (2011) evaluated 13 
women for the meanings of menopause in a qualitative study.  Hall, Callister, Berry, and 
Matsumura (2007) described the attitudes and sociocultural influences in women in the 
management of menopause within the literature utilizing Meleis’s transition theory.     
The transition theory includes the property of awareness is defined as a perception, 
knowledge, and recognition of a transition experience and level of awareness, as this relates to 
what is known about the process and responses of the individuals undergoing similar transitions 
(Meleis et al., 2000).  The property of awareness can be associated with a woman experiencing 
hot flashes or changes specific to her menstrual cycle, from regular to varying in time of onset.  
The property of engagement is referred to as the degree in which a woman demonstrates 
involvement in the process inherent in the transition, a level of awareness related to a level of 
engagement (Meleis et al., 2000).  The woman with a level of engagement is aware of physical 
and emotional changes specific to her body, as they relate to menopausal symptoms. 
Perimenopause and menopause are also considered periods of time for women that are normal 
life transitions (Meleis, 2010).  
Background 
The background for this project focuses on the symptoms of menopause, treatment of 
menopause and the prescribed pharmaceutical hormone replacement therapy utilized.  The 
prescribed pharmaceutical hormone replacement therapy was addressed and included synthetic 
preparations known as Premarin, and compounded hormone therapies known as bioidentical 
hormones (BH).  Compounded hormones have increased in utilization because of the initial 
results from the Women’s Health Initiative (WHI) (2002), as a result of celebrity endorsements, 
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media coverage, and expansion of bioidentical hormone therapy industry (Files, Ko, & Pruthi, 
2011). 
Chapter 2 
Review of the Literature 
 The literature review is arranged to address BH, the main areas of menopause, traditional 
hormone replacement therapy, and establish a framework to guide the research investigation.  
The information presented includes bioidentical hormones, physiology of perimenopause, 
physiology of menopause, the effects of menopause, osteoporosis, diagnosis of osteoporosis, the 
landmark studies specific to osteoporosis, the results of estrogen loss and the development of 
insulin resistance, the landmark studies related to insulin resistance, and the development of 
cardiovascular disease and the landmark studies, stroke,  venous thrombosis, and breast cancer. 
The use of hormone replacement therapy including study results, the current controversies 
surrounding BHRT, BHRT studies, and the current recommendations for treating women with 
menopausal symptoms were addressed. 
Bioidentical Hormones 
 The impact of the WHI (Rossouw et al., 2002), study resulted in women discontinuing 
hormone replacement therapy (HRT), while moving to an alternative form of treatment, known 
as compounded bioidentical hormones (CBH) (Cirigiliano, 2007).  Additionally, the celebrity 
books by Suzanne Somers The Sexy Years, and Michael Platt’s The Miracle of Bioidentical 
Hormones, spurred interest for women seeking an alternative form of treatment for menopausal 
symptoms post WHI results (Cirigiliano, 2007).  Subsequently, Somers wrote another book 
Ageless: The Naked Truth About Bioidentical Hormones, supporting the use of bioidentical 
hormones as reversing the aging process, keeping one mentally sharp, physically fit, and sexually 
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active, with no clinically proven data to support her statements (Cirigiliano, 2007). 
 The process of compounding is described as the mixing of a drug by a pharmacist with a 
licensed practitioner’s prescription.  The pharmaceutical companies accepted most of the 
compounding in the 1900’s, resulting in a decrease of compounding by pharmacists.  The United 
States Food and Drug Administration (USFDA) supports the compounding of prescriptions as 
being ethical and legal (Pegues, 2006), while it is estimated that 1% of prescriptions in the 
United States, (approximately 30 million per year) are compounded (Endocrine Society, 2006).  
The practice of compounding is also popular in Europe (Cirigiliano, 2007). 
 Bioidentical hormones (BH) are characteristically derived from plant extracts and 
chemically altered to be identical in structure to endogenous human hormones (Cirigiliano, 2007; 
Sites, 2008).  The sources of these hormones include plants from soy or yam, with a fundamental 
primary concept being supported that isomolecular hormones are identical to those found in a 
woman and therefore are better tolerated and more appropriate to treat menopausal symptoms 
(Lorentzen, 2001; Walker, 2001).  Compounded bioidentical estrogens include estrone (E-1) and 
estradiol (E-2). Prior to January 2008, estriol (E-3) was available (Eichelsdoerfer, 2008). These 
estrogens (estriol, estradiol and estrone), when combined, are referred to as “biest” (bi-estrogen) 
with estriol and estradiol and “tri-est” with all three estrogens (Eichelsdoerfer, 2008).   
Bioidentical hormones have been traced to Jonathan Wright, as he described the 
physiologic difference noted between patentable and un-patentable hormones (Wright & 
Morganthaler, 1997; Wright, 2005). Boothby, Doering, and Kipersztak (2004), defined 
bioidentical hormone replacement therapy (BHRT) as hormone treatment with individually 
compounded recipes of certain steroids in various dosage forms, that include dehydro-
epiandrosterone (DHEA), pregnenolone, testosterone, progesterone, estrone, estradiol, and estiol; 
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and the use of the term “natural” refers to steroid hormones occurring naturally in women and 
not in reference to phytoestrogens (Boothby et al., 2004).  Fugh-Berman and Bythrow describe 
BH as “pseudoscientic” referring to endogenous hormones which are synthesized or semi-
synthesized (2007).   
The dose, regimen, and dosage forms are then customized to treat a menopausal woman’s 
symptoms, based on hormonal levels, symptoms, and their preferences, also referred to as 
personalized medicine (Ruiz, Daniels, Barner, Carson, & Frei, 2011).  Bioidentical hormones are 
mixed by a compounding pharmacist, based on a physician’s orders, and administered via 
transdermal, vaginal, or sublingual routes (Mahmud, 2010).  Advocates of custom BHRT claim 
they offer improved safety, efficacy, and tolerability because of the formulas being 
individualized, the source of the hormones and the routes of delivery (Boothby et al., 2004). 
Physiology of Perimenopause  
Perimenopause is known as the physiologic response to the fluctuation of hormones and 
associated with menstrual cycle irregularity (Bosarge & Freeman, 2009).  Perimenopause 
signifies “around menopause” and denotes the phase during the time which a woman’s body 
creates her natural change toward permanent infertility (menopause). Perimenopause is also 
known as “menopausal transition”, the time leading up to menopause (Nelson, 2008).  The 
physiology of perimenopause is often evident by irregular menses, until 12 months after the final 
menstrual cycle, when a woman is then considered menopausal (National Institutes of Health 
State, 2005). 
The symptoms frequently associated with the onset of perimenopause include irregular 
menses, vasomotor changes (night sweating and hot flashes), vaginal dryness, mood swings, 
disruptive sleep patterns, genitourinary changes, sexual dysfunction, anxiety, noticeable changes 
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in skin characteristics, decreased concentration and depression (Plonczynski & Plonczynski, 
2007).  Hot Flashes are among the most commonly reported perimenopausal symptoms 
worldwide and this incidence is one of the motivating reasons for women seeking therapeutic 
treatment (Nakano, Pinnow, Flaws, Sorkin, & Galliccihio, 2012).  An anticipated 1.2 billion 
perimenopausal or postmenopausal women will be affected by hot flashes by 2030 (Lewis, 
2009).  Hormone therapy has been used to avert and/or treat the various health variations during 
perimenopause and subsequent to menopausal transition (Parke & Abernethy, 2008). 
Physiology of Menopause 
The average age for natural menopause in the US is 51 (NAMS, 2013).  Menopause 
develops from the reduced secretion of the ovarian hormones estrogen and progesterone, which 
occurs as the number of ova present in the ovaries of a female precipitously decreases and 
declines during the reproductive years and the finite ovarian follicles are depleted (Nelson, 
2008).  The original balance among the hormones estrogen, progesterone, follicle stimulating 
hormone (FSH), and luteinizing hormone (LH) convert to a varying slightly estrogen and/or 
progesterone may begin to cycle at lower than usual levels, while FSH and/or LH levels may rise 
slightly higher to compensate, while cycling of the menses still continues (Wright & Leonard, 
2010).  With the onset of menopause, menstrual cycle lengths vary in irregularity, and the FSH 
concentrations rise in reaction to the decreased concentrations of ovarian hormones (Nelson, 
2008).  The cessation of menses and estrogen production is the finality of menopause.   
Natural menopause follows 12 months of amenorrhea from the last menstrual period 
(North American Menopause Society (NAMS, 2007).  Premature ovarian failure, known as early 
menopause, is the result of the cessation of ovarian function in women under the age of 45 
(Holloway, 2011).  The average American woman usually experiences menopause around age 51 
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(Morrow, Mattar, & Hortobagyi, 2011), however, this is determined by genetics, environmental 
factors such as smoking, and surgery (oophorectomy), chemotherapy or radiation therapy (Rees, 
Stevenson, Hope, Rozenburg, & Palacio, 2009).  The menopausal age differs around the world 
and is described to be at age 48 in Mexico, 45.8 in Turkey, and age 49.3 in Korea (Melby et al., 
2005).    
 The symptom of hot flashes is one of the well-known occurrences of menopause, which 
occurs in >75% of menopausal women and has a tendency to be most severe in the first two 
years of menopause (Nakano et al., 2012).  Hot flashes occur with differing severity and 
frequency from anytime day or night, and can be complemented by sweating, tachycardia, 
palpitations, anxiety, irritability, and feelings of panic.  Hot flashes can average up to four 
minutes and range in duration from a few seconds to ten minutes, while night sweats can be 
associated with hot flashes or occur independently (Hickey, Davis, & Sturdee, 2005).  The 
physiological decline of estrogen as a result of menopause is correlated with increased risk for 
major health variations comprising of osteoporosis, cardiovascular disease (CVD), and diabetes, 
(Nelson, 2008; Shoupe, 2012).   
Effects of Menopause 
Osteoporosis  
Osteoporosis is the most prevalent health variation as the hormonal influence of estrogen 
on bone health dissipates with the onset of menopause.  The progressive changes in bone 
structure, quality and density lead to pathological fractures and an increase in morbidity and 
mortality among menopausal women (Christenson, Jiang, Kangan, & Schnatz, 2012).  It is 
estimated that 13% to 18% of women in the United States, who are at least 50 years old, have 
osteoporosis, and an additional 37% to 50% have osteopenia, which is the presence of less than 
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the normal amount of bone mass.
 
 Osteoporosis causes one million fractures yearly, and the 
mortality rate following a hip fracture is 12% to 20%.  Hip fractures in postmenopausal women 
is the second leading cause of admission to nursing homes and is one of the major disorders that 
contributes to the loss of independence and quality of life (NAMS, 2010). 
 Bone remodeling is a combined process of bone resorption followed by bone formation. 
Osteoclasts promote bone resorption at the cellular level by stimulating the production of acid 
and enzymes that dissolve bone mineral and proteins.  The events occur when there is an 
imbalance between bone resorption and bone formation, thereby resulting in a decrease of bone 
mass and the increased risk of fracture from bone loss (NAMS, 2010). 
 Bone health is known to be influenced by several hormones regulating the process of 
bone resorption and formation, including the sex steroid hormones of testosterone and estrogen 
(Department of Health and Human Services (DHHS, 2004).  Estrogen deficiency is associated 
with disease states such as Turner’s syndrome, athletic amenorrhea or anorexia nervosa during 
this time, and is linked to low bone mass (Lindsay, 2004).  Menopause is associated with 
increased rates of bone turnover and rapid spurts of bone loss from the decline of estrogen. The 
reduction in the estrogen receptors in bone is believed to be a primary factor in this large 
increase in bone resorption with reduced bone formation at menopause (DHHS, 2004).  The 
addition of hormone therapy (HT) in women who are on average a decade past menopause 
(mean age of 63 years) preserves bone integrity, prevents bone loss and reduces the risk of 
fractures (DHHS, 2004).   
Bone loss in older women may also be affected by the decreased dietary intake of 
calcium, vitamin D, and decreased physical activity, all of which contribute to maintaining bone 
health (NAMS, 2010).  The amount of estrogen loss can affect the absorption of vitamin D and 
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calcium, which will then result in the interference of bone formation.  Additionally, conditions 
affecting the absorption of food, including ulcerative colitis, Crohn’s disease, gastric surgery, 
and liver disease contribute to the development of osteoporosis (Holloway, 2011).  A 
menopausal woman with the following associated conditions is also at increased risk for 
osteoporosis: thin build, weight loss, anorexia, and low body mass index (Rees et al., 2009). 
Diagnosis of Osteoporosis 
Bone of the hip and spine is tested through densitometry also referred to as Bone Density 
Scan (DEXA).  The measurement is represented by a T-score or a Z-score. The number reported 
represents the amount of bone in comparison to a young adult of the same gender with peak bone 
mass.  A score above -1 is considered normal, while a score between -1 and -2.5 is classified as  
osteopenia (low bone mass), and an osteoporosis score is below -2.5.  The T-score is used to 
estimate a woman’s risk of developing a fracture, and a Z-score may indicate the need for further 
testing (Radiological Society of North America, 2014). 
Bisphosphonates are deemed as first line therapy in the treatment of osteoporosis and 
reduce spine fractures by 40% to 70% and hip fractures by 20% to 35% (Christenson et al., 
2012).  Selective estrogen receptor modulators (SERMs), known as raloxifene (Evista), 
lasofoxifene and bazedoxifene, lower the risk of vertebral fractures in postmenopausal women 
(Archer et al., 2011).  The current National Osteoporosis Foundation (NOF) guidelines state 
treatment with pharmacological agents should be considered in postmenopausal women aged  
≥ 50 years who present with hip or vertebral fracture; T score ≤ -2.5 at the femoral neck, total 
hip, or spine post evaluation; or low bone mass and a 10-year probability of hip fracture ≥ 3% or 
a 10 year probability of major osteoporosis related fracture ≥ 20% based on the  Fracture Risk 
Assessment Tool (FRAX) calculation (National Osteoporosis Foundation, 2008).  
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Another method for predicting bone loss is serum C-telopeptide (CTx) which is a 
reference bone marker for resorption.  The CTX marker was found to be most sensitive and a 
better marker for bone mineral density (BMD) by Garnero, Sornay-Rendu, Duboeuf, and Delmas 
(1999).  Bone turnover markers such as CTx were found to be useful and may assist in the 
prediction of menopausal women for osteoporosis (Garnero, 2008).   
Landmark Studies Related to Osteoporosis  
The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, the National Heart, 
Lung, and Blood Institute (NHLBI) and the National Institutes of Health (NIH) initiated a major 
clinical trial in 1987, known as the PEPI trial. The trial was conducted at seven clinical sites 
across the United States, and included 875 healthy postmenopausal women, ages 45-64, who 
were followed for three years.  The women were predominately white, but included a variety of 
races, while a third had undergone a hysterectomy (The Writing Group for the PEPI Trial, 1996).  
The four hormone options in the PEPI trial were: 1) Premarin (conjugated equine estrogens CEE) 
only daily, 2) Premarin (CEE) and Progestin (medroxyprogesterone acetate), both daily, 3) 
Premarin (CEE) daily and synthetic Progestin 12 days per month; and 4) Premarin (CEE) daily 
and micronized progesterone 12 days per month; or 5) placebo. 
In the PEPI trial women were evaluated for bone mineral density (BMD).  Those 
assigned to the placebo group experienced a loss of 1.8% of spine BMD and 1.7% of hip BMD 
on the 36-month visit. Conversely, women with regimens increased their spinal BMD from 3.5% 
to 5.0% and experienced a 1.7% mean increase of BMD in the hip.  The women assigned to 
estrogen (CEE) daily plus medroxyprogesterone had significant increases of 5% spinal BMD 
with average increase of 3.8% (Miller & Franklin, 1999).  
The Danish Osteoporosis Prevention Study (DOPS) was a randomized controlled trial 
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that included 1006 younger women at the onset of menopause treated with oral estradiol and 
norethindrone acetate or estradiol alone for ten years, and who were followed for up to 16 years 
to assess osteoporosis.  The findings of the study did not report any results related to 
osteoporosis outcomes (Schierbeck et al., 2012).  Data from 2004-2005 revealed that age-
adjusted osteoporosis-related fractures had risen, compared to 2000-2001 (Islam, Liu, Chines, & 
Hetzer, 2009) while an observational study of 80,955 women over 6.5 years, who had 
discontinued treatment, where found to that have an increased rate of hip fractures compared to 
women that continued taking hormone treatment (Karim, Dell, Greene, Mack, Gallagher, & 
Hodis, 2011). 
Results of Estrogen Loss 
Insulin Resistance  
 Menopause can be considered a risk factor for CAD in women as a result of the potential 
effects of ovarian failure on cardiovascular function, blood pressure and the assorted metabolic 
parameters of glucose tolerance and lipid profiles.  Prevention strategies for menopausal women 
should include the reduction of blood pressure, weight control and controlling glucose 
metabolism (International Menopause Society Writing Group (IMSWG), 2011). 
 The incidence of abdominal obesity is a known-risk factor for metabolic and 
cardiovascular diseases (Despres, Moorjani, Lupien, Tremblay, Nadeau, & Bouchard, 1990; 
Despres, 1993).  The cause of menopause-transition effects with metabolic disease is unclear 
however the association may be related, to body fat distribution increased abdominal adipose 
tissue related to metabolic syndrome, involving type 2 diabetes, hypertension, and dyslipidemia 
(Despres, 1993; Despres et al., 1990; DeFronzo, 1997).  Estrogen utilizes anti-diabetic measures 
by mechanisms that affect glucose homeostasis (Louet, LeMay, & Mauvais-Jarvis, 2004).  The 
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reduction of peripheral insulin sensitivity, increased hepatic clearance of glucose and reduced 
pancreatic secretion of insulin in post-menopausal women has been described as the loss of 
estrogen may influence these alterations (Toth, Tchernof, Sites, & Poehlman, 2000). 
Insulin Resistance Results in Landmark Studies  
Clinical trials in postmenopausal women with estrogen (ET) and estrogen with progestin 
therapies (EPT) have given positive evidence for the promising effect of estrogen on glucose. 
The findings from a prospective randomized controlled PEPI trial found that all women 
receiving estrogen regimens had a reduction in fasting glucose levels, however blood glucose 
two hours after eating seemed to be elevated (The Writing Group for the PEPI Trial, 1996).  The 
Heart and Estrogen Progesterone Replacement Study (HERS), the Women’s Health Initiative, 
and the Kronos Early Estrogen Prevention Study (KEEPS) were randomized controlled clinical 
trials, revealing favorable benefits with estrogen therapy on glucose metabolism in 
postmenopausal women (Herrington et al., 2000; Kanaya et al., 2003; Margolis et al., 2004; & 
Lobo, 2013).  
 Clinical trials have shown the benefit of hormone replacement therapy has had favorable 
results on body composition, where a significant increase in fat mass and trunk fat has been 
reported in the control groups after five years (Norris, Joyce, O’Keefe, Sheppard, & Booner, 
2002).  Abdominal obesity research has been studied in menopausal women evaluating body 
mass index (BMI), waist circumference, fat-mass, lean mass and physical activity related to fat 
distribution.  Results found that increases in visceral adiposity are associated with insulin 
resistance, hypertension, and hyperlipidemia, as seen in studies by (Despres, 1993, Despres et al., 
1990; & Franklin, Ploutz-Synder, & Kanaley, 2009). 
 The favorable outcome of the significant decrease for diabetes mellitus incidence in the 
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estrogen progesterone therapy group in the HERS and Women’s Health Initiative (WHI) trials 
compared to the placebo group is undeniable (Kanaya et al., 2003; Margolis et al., 2004).  These 
results support the function of estrogen progesterone therapy (EPT) in the prevention of DM in 
postmenopausal women, however beneficial, EPT in postmenopausal women is associated with 
greater rates of adverse events for heart attack, stroke (cardiovascular events) and breast cancer 
incidence, and is therefore not considered to be safe for the improvement of health in 
postmenopausal women (Rossouw et al., 2002).  
Cardiovascular Disease  
  The four contributing risk factors: hyperlipidemia, hypertension, obesity, and diabetes are 
primarily nutritional in origin however these risk factors are associated with increased risk for 
developing cardiovascular disease (Franco, Cooper, Bilal, & Fuster, 2011).  The incidence of 
cardiovascular disease (stroke, and coronary heart disease) is rare in women before menopause, 
but is the most common cause of death in women over the age of 60, while coronary heart 
disease is the single most common cause of death in women over age 60 (Brockie, 2008).  The 
alterations caused by atherosclerotic changes to the coronary arteries, resulting in ischemic 
damage to the myocardium, presenting in women eight to ten years later than men (Schenck-
Gustafsson, 2007). 
 The associated changes in lipid metabolism and higher levels of lipoprotein (a) linked 
with increased atheroma, changes in carbohydrate metabolism with increasing insulin resistance, 
hyperlipidemia, diabetes, hypertension, and obesity are associated with lower estrogen levels 
after menopause (Jackson, 2008).  Additionally women with high C-reactive protein are at 
increased risk for cardiac and vascular events, with raised homocysteine levels (Brockie, 2008). 
Finally, the life-style risk factors associated with the increased risk for coronary heart disease are 
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smoking, stress and depression (Jackson, 2008). 
Cardiovascular Disease and Landmark Studies 
 The PEPI trial followed 875 healthy, post-menopausal, predominately white women, ages 
45-64 for three years. The goal was to see the effects of various hormone regimens on the key 
risk factors for heart disease.  The initial results revealed estrogen-only therapy raised the level 
of good high density lipoprotein (HDL); insulin levels were not affected with any of the hormone 
regimens; and all of the hormone regimens caused an increase in triglyceride levels. 
Uncertainties regarding hormone replacement therapy and their effects of how long and at what 
age a woman should start hormone therapy, reducing heart attacks and strokes was one of the 
outcomes from the PEPI trial (The Writing Group for the PEPI Trial, 1996). 
 The initial results of the WHI and the coronary findings were of borderline significance 
1.24 (1.00-1.54) (Manson et al., 2003).  The findings of the WHI were varied according to 
Stevenson, Hodis, Pickar, and Lobo (2009).  In a study by Weinberg, Young, Hunter, Agrawal, 
Mao, and Budoffet (2012), of the WHI, coronary calcium scores were significantly reduced in 
women taking estrogen, thereby leading to a statistically significant reduction in coronary 
disease.  The sub-analyses of large randomized trials are suggestive of coronary benefits in 
younger menopausal woman receiving estrogen therapy however this should be interpreted with 
caution (Lobo, 2013).  
 Looking at the WHI 10 years later, a follow-up-of women in the estrogen-alone trial 
revealed that women aged 50 to 59 years had a significantly reduced rate of myocardial 
infarction (MI) and coronary heart disease (CHD), and a 30% reduction in all-cause mortality 
(LaCroix, Chlebowski, & Manson, 2011).  The hypothesis of “timing” recommends younger 
symptomatic women at the onset of menopause may be protected from CHD, where an older 
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group of women, who were treated initially, may experience early harm.  Lastly women who 
were older and treated for the first time with estrogen may have no benefit from HT (Lobo, 
2013). 
Stroke  
Hormone therapy and the effects of stroke are controversial, because of the numerous 
variables confounding the data (obesity and hypertension) and the risk of marginal significance 
that exists (Lobo, 2013).  Ischemic stroke (not hemorrhagic stroke) has shown a small increase in 
younger women receiving standard doses of oral estrogen by approximately 30% in 
observational data.  Women have a reduced rate of stroke incidence compared to men up until 
the age of 85 years or older.  The incidence for ischemic stroke in women age 55 to 65 years old 
is three in 1000, however the risk nearly double during the menopausal transition period and 
continues to increases with age (Bushnell, 2009).  The mechanism for the increased risk of 
ischemic stroke in the younger menopausal woman is thrombotic and not atherosclerotic as in 
older women and may be in origin of thrombophilic sensitivities (Sare, Gray, & Bath, 2009).   
Stroke was reported in the WHI clinical trial results revealing an overall increase in the 
menopausal group that received Estrogen CEE + MPA, and an increased risk was less evident in 
the younger menopausal group of women (Rossouw et al., 2007).  The risk for stroke in women 
nearly doubles between the ages of 55 and 65 years, which is consistent with at least 10 years 
after the age of menopause (Bushnell, 2009).  There are only a few studies examining the 
association between age at menopause and stroke (Jacobsen, Heuch, & Kvale, 2004; de 
Lecinana, Egido, & Fernandez, 2007; Hu, Grodstein, & Nennekens, 1999). 
Venous Thrombosis 
 The relevancy of ischemic stroke in menopausal women who use hormone therapy is 
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related to the findings of venous thrombosis risk.  In the WHI (Rossouw et al., 2002), the risk for 
venous thromboembolism with standard doses of oral estrogen was found to have increased by 
33% with a more than two-fold increase, with most incidences occurring within the first two 
years of therapy; while the addition of micronized progesterone the risk increased to 59% 
compared with conjugated equine estrogen (CEE) alone and no mortality changes were reported 
(Curb et al., 2006).  The estrogen-alone trial of the WHI revealed a more obese cohort, with 
numerous women in this group having had a hysterectomy and previous exposure to hormones 
(Rossouw et al., 2002). 
 The use of oral estrogen increases the risk for thrombosis.  Standard doses of oral 
estrogen increase the risk of venous thromboembolism approximately two-fold, as was observed 
in the WHI trial (Rossouw et al., 2002).  Most cases were reported in the first or second year of 
therapy, with no changes in mortality (Lobo, 2013).  The use of transdermal estrogen is not 
associated with an increased risk for thrombotic events (Olie et al., 2011).  Researchers have 
steadily revealed a twofold increase in the risk for venous thromboembolism (VTE) with HRT 
use (Cushman, Kuller, & Prentice, 2004; Canonico, Oger, & Plu-Bureau, 2007). 
Breast Cancer 
 The fear women experience in regards to hormone therapy (HT) is the potential for 
developing breast cancer (Walsh-Childers, Edwards, & Grobmyer, 2011).  The incidence for 
breast cancer among women utilizing estrogen was initially described by Hoover, Gray, Cole, 
and MacMahon (1976).  In a case-controlled study by Ross et al., (1980), 138 women with breast 
cancer were reported and the risk ratio for cumulative estrogen doses larger than 1500 mg versus 
no hormone therapy was 2.5.  Pike, 1983 and Bergkvist, Adami, Persson, Bergstrom, and 
Krusemo (1989) found a small increased risk of breast cancer related to hormone therapy with 
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longer durations of their use, compared to no hormone therapy.  
  In 1995, the prospective Nurse’s Health Study (established in1976) was published to 
quantify the relationship between the use of hormones and the risk for breast cancer in 
postmenopausal women.  The researchers confirmed there was a greater risk for increased breast 
cancer incidence among older women taking hormones after menopause and a stronger risk was 
seen with five or more years of hormone use, specifically among women using estrogen plus 
progestins.  Colditz et al., found the risk for estrogen alone increased the risk for breast cancer 
(1995). 
In another study, a Collaborative Group on Hormonal Factors in Breast Cancer in 1997 
consolidated data from previous case-controlled studies of 52,705 women.  Women with breast 
cancer and 108,411 control subjects revealed a significant increase for the risk of breast cancer 
and the increased risk was associated with the duration of estrogen use (Chlebowski & 
Anderson, 2012).  There are many issues one must consider when assessing a woman’s risk of 
developing breast cancer with HRT use.  Age is an important risk factor and most studies report 
an increased risk in older women (Parke & Abernethy, 2008). 
 The Million Women Study, a population-based cohort study of women between the ages 
of 50-64, was completed in the United Kingdom.  800,000 women were recruited with 33% who 
were utilizing HRT currently while there were 47% that had used HRT at some time in the past 
(Banks, Beral, & Reeves, 1999).  The main purpose of the study was to examine the relationship 
between breast cancer and the use of HRT.  As one of the largest studies ever conducted, the 
findings yielded higher breast cancer mortality for women who were diagnosed with breast 
cancer while using estrogen plus progestin compared to the non-hormone therapy group (Beral, 
2003). 
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 The WHI reported a significant increase of 26% in the relative risk in duration effect for 
invasive breast cancer in women between the ages of 50-79 years old with the treatment of oral 
conjugated equine estrogens (CEE) plus medroxyprogesterone acetate, versus the placebo group 
in the study (Stevenson et al., 2009).  Later, in a subgroup analysis, the initial increased risk of 
breast cancer was only seen in those who had used HRT before entering the study, suggesting 
that up to four years of exposure to combined HRT did not lead to an increased risk for breast 
cancer, while the type and dose of progestin and estrogen may affect the risk for breast cancer 
(Hickey et al., 2005). 
Hormone Replacement Therapy 
  Hormone replacement therapy, and/or menopausal hormone therapy (MHT), are 
medications that combine the hormones estrogen and progestin (synthetic forms of 
progesterone), and on occasion, are used with testosterone (Garad, Burger, & Davison, 2011).  
Oral estrogen preparations include: conjugated equine estrogens (CEE), synthetically derived 
piperazine estrone sulphate, estriol, micronized estradiol, and estradiol valerate (Hickey et al., 
2005).  Other forms of HRT include: estradiol in a patch, gel, a slow-release percutaneous 
implant, or nasal spray.  There are also intravaginal forms of estrogens that include rings, 
creams, topical, tablets, and pessaries (Smith & Wein, 2010). 
Hormone replacement therapy has been utilized as the initial line of treatment for the 
relief of menopausal symptoms (Buist et al., 2004).  The increasing life expectancy among 
women, and the incidence of osteoporosis and cardiovascular disease justified the popularity of 
HRT prescribed for symptom relief and chronic disease prevention that was seen in the 1990’s 
(Garard et al., 2011).  Hormone replacement therapy has been used to prevent or treat the 
numerous health alterations of erratic or excessive vaginal bleeding, vasomotor symptoms of 
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night sweats and hot flashes associated with menopause (North American Menopause Society 
(NAMS, 2005). 
          Between 1999 and 2000, 38.3% of women age 50-59 utilized HRT.  A decade later (2000-
2010) in the same age group, only 6.7% reported taking HRT, while currently, 4.7% of women 
over 40 seek HRT (Sprague, Trentham-Dietz, & Cronin, 2012).  The reported drop in hormone 
therapy was linked to the results of the WHI, 2002 and physicians discontinuing HRT in 
menopause women (Endocrine Society, 2006).  The Food and Drug Administration (FDA) 
requires manufacturers of FDA-approved estrogen and progesterone products to use class 
labeling, also known as black box warning, indicating a drug with special problems, particularly 
possibly leading to death or serious injury subsequent to the results of the WHI (U.S. Food and 
Drug Administration (USFDA), 2008).  While on the tenth anniversary of the WHI 2002 trial, 
the consistent theme exists much has been learned and yet the experts “don’t agree” regarding 
the safety and efficacy of HT from previous and ongoing studies to date (Stuenkel et al., 2012). 
Controversies Related to Compounded Bioidentical Hormones 
The U. S. Food and Drug Administration (FDA) responded to a citizen’s petition in 2005 
on behalf of Wyeth Pharmaceutical.  The petition filed by Wyeth was against the manufacturing 
and marketing of compounded BHRT (USFDA, 2008).  Wyeth produces the drug Premarin 
which is a conjugated estrogen and other contraceptives (Wyeth, 2014).  The drug (Premarin) 
was associated with negatives outcomes from the WHI, HERS, and PEPI trials (Rossouw et al., 
2002).  Subsequently, the FDA warned against the inclusion of estriol in compounded 
preparations, and issued warning letters to nine compounding pharmacies in the United States 
following the Wyeth petition (USFDA, 2008). 
 The compounding of medications continued, until an incident lead to the deaths of 25 
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patients and 344 patients diagnosed with fungal meningitis due to the contamination of a batch of 
injectable medication produced by the New England Compounding Center (NECC) in 
Framingham, Massachusetts (Savage, 2012).  This led to the scrutinized practice of 
compounding (Savage, 2012).  The Centers for Disease Control and the U.S. Food and Drug 
Administration (FDA) confirmed the incidence of a fungus in unopened vials of preservative-
free methylprednisolone acetate from one of the three implicated lots from the NECC, 
furthermore laboratory confirmation linked the outbreak of fungal meningitis (Food and Drug 
Administration (FDA), 2012). 
Subsequently, the FDA instituted a new law in November 2013, enacting the Drug 
Quality and Security Act (HR 3204), signed by President Barak Obama, the compounding track-
and-trace legislation.  This law has impacts to compounding pharmacies such as voluntary elect 
to be “outsourcing facilities” regulated by state boards of pharmacy and the FDA.  The FDA has 
to determine how the implementation of the regulatory process will occur, while traditional 
pharmacies and compounding pharmacies will continue to be regulated by state boards of 
pharmacy (Yap, 2014). 
Current Recommendations for Menopause Symptoms 
 The American College of Obstetricians and Gynecologists and the American Society for 
Reproductive Medicine Practice Committee recommend that women be counseled on 
menopausal therapies proven to be safe and effective by the FDA.  Physicians should practice 
caution in prescribing compounded hormones when FDA-approved alternatives exist.  The 
following FDA approved products include Estradiol (transdermal or oral, micronized), Estrone 
(active ingredient in conjugated equine estrogen preparations), and progesterone (oral, 
micronized or vaginal gel or insert) (American College of Obstetricians and Gynecologists 
(ACOG), 2012). 
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 The US Preventive Services Task Force (USPSTF) recommended against the use of 
estrogen alone and combined estrogen and progestin for the primary prevention of chronic 
conditions in postmenopausal women (2012).  However, the USPSTF did not examine the data 
related to the use of hormone therapy for the treatment of women with menopausal symptoms of 
hot flashes or vaginal dryness.  Additionally, the USPSTF recommendations are not relevant to 
women younger than 50 years of age who have undergone surgical menopause (2012). 
 The findings from the WHI trial reported new information regarding the age of the 
participants and the time from menopause to initiating hormone replacement therapy.  This has 
now become relevant to the outcomes initially reported.  The recently updated information 
revealed the study group was an older population and therefore this may have changed the 
outcomes of the WHI study (Lobo, 2013).  While on the tenth anniversary of the WHI 2002 trial, 
the consistent theme exists that much has been learned and yet, the experts “don’t agree” 
regarding the safety and efficacy of HT from previous and ongoing studies to date (Stuenkel et 
al., 2012). 
Bioidentical Hormone Studies 
Bioidentical hormone trials include a randomized blinded four-arm 16-day clinical trial 
of forty postmenopausal women that were assigned to one of three different doses of a 
compounded estrogen cream known as Bi-est, + compounded oral progesterone, or a 
conventional estradiol patch such as Vivelle-Dot + Prometrium (Sood et al., 2013).  The goal of 
the researchers was to compare the pharmacokinetics of conventional and compounded hormone 
preparations.  All study medications were prepared and dispensed by the same compounding 
pharmacist, thereby minimizing variability in the compounding medications.  The absorption 
patterns with Biest creams were found to be highly variable and no peak absorption was 
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observed, while the small increments in estradiol levels with low-dose Biest formulations raised 
the question of how much symptomatic benefit is credited to doses derived from a placebo effect.  
The findings raised a question as to whether the compounded formulation doses are sufficient to 
provide any bone benefits in menopausal women (Sood et al., 2013).  
 An observational cohort study of women, between the ages of 18-89, who received a 
compounded BHRT product from January 1, 2003 to April 30, 2010, from six community 
pharmacies was conducted.  The data included patient demographics, comorbidities, therapeutic 
outcomes, and hormone therapies, women self-rated menopausal symptoms, and descriptive 
statistics were used to characterize the data and adverse events.  The study included 296 women 
who received BHRT from Oakdell Pharmacy with a mean age of 52.  Reported results included a 
25% decrease in irritability and 22% reduction in anxiety within three to six months of treatment.  
Bioidentical hormone replacement safety from this cohort of women had documented follow-up 
for 1.9 years regarding MI and breast cancer, with no women experiencing MI or breast cancer.  
While the results are promising, larger studies of women need to be conducted for a longer 
period of time to examine the impact of BHRT on vasomotor symptoms, MI, and breast cancer 
(Ruiz et al., 2011). 
 The review of the literature includes relevant research that has led to the related project.  
Research regarding the safety of BHT is sparse; some of the existent literature focuses on the 
pharmacodynamics and therapeutic reports for relief of symptoms over short time periods.  
Therefore the need to research the topic of safety of BHT is requisite. 
Problem Statement and Research Question 
  The review of the literature reveals BHRT for the treatment of menopause symptoms has 
benefits for the improvement of symptoms however the lack of safety data is a concern 
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(Cirigiliano, 2007).  Limitations with the current research include the lack of clinical studies with 
the use of Biest (Estriol and Estradiol), and Triest (Estriol, Estradiol, and Estrone) with or 
without Progesterone.  No studies state the safety for the use of BHRT.  The purpose of this 
project was to investigate if the use of Biest and Progesterone after four years or longer increased 
the risk for osteoporosis, breast cancer and cardiovascular disease. 
Chapter 3 
Methods 
Project Design 
  A cohort retrospective descriptive chart review was utilized for this study.  The study 
included menopausal women that utilized BHRT specifically Biest and Progesterone for four or 
more years.  A retrospective study design utilizes existing data, and for this project served as a 
useful purpose to evaluate BHRT use over a time period of four or more years. 
Setting 
The setting was a conducted in a practice that prescribed and treated women with BHRT.  
The practice was in existence for thirteen years, and had three physicians, one naturopath, and 
one nurse practitioner, each prescribing BHRT when indicated.  The practice did not accept 
medical insurance and required payment at the time services were rendered.  The practice was 
located in Southern California and has a Northern California office location, however for the 
purpose of the study only the Southern California office was utilized. 
Sample 
 The population was identified by the Compounder Four System (Compounder 4), a 
computerized system for prescriptions in the dispensary at Southern California private practice.  
The population was menopausal women between the ages of 40 and 70, who were prescribed and 
utilized BHRT.  The Compounder Four System generated a list of women seen in the practice 
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who met criteria from January 2008 to October 2014.  The population consisted of women who 
were able to pay for services at the time of their visit.  The office did not collect data on racial 
background or demographic data, thus this information was excluded. 
Instrumentation 
There was one survey tool utilized for the study.  A 20 question tool was developed based 
on the initial patient questionnaire from the practice setting, and subsequently additional 
information was added to determine if incidences for osteoporosis, breast cancer, or MI had 
occurred, based upon the literature reviewed.  See Appendix A for the tool.  The physician 
director of the practice provided written consent for the study to be conducted in his office.  The 
original document was revised for the study and verbal consent was given for the use of 
questions from the initial patient questionnaire.  Since the revised tool was not utilized in 
previous studies and was not tested for reliability, it was piloted during the study.   
Data Collection 
A chart review was conducted once the inclusion criteria were met for women who used 
Biest and Progesterone for four years or longer.  The patients were identified utilizing the 
Compounder Four (Compounder 4) compounding system used in the dispensary of the Southern 
California private practice where the study was conducted.  A list was generated from the 
Compounder Four system and charts were reviewed from those individuals meeting inclusion 
criteria.  A chart review was then conducted once the inclusion criteria was met by the primary 
investigator to verify that inclusion criteria had been met for continuous Biest and Progesterone 
use for four or more years, utilizing the Compounder four system and pharmacy renewal 
verification from the subjects chart.  The developed tool and a tool for each patient’s chart were 
utilized to maintain accurate data collection.  Basic demographic data without patient identifiers 
were also part of the data collected. 
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Data Collection Procedures 
 Data was coded (de-identified).  Each chart identified by the Compounder Four System 
was reviewed by the primary investigator for inclusion criteria.  Once the chart and data from the 
Compounder Four System had been verified the chart review tool was used and data was then 
collected.  Once data was collected data was then entered into an excel file with de-identified 
information.  Data was stored in a locked filing cabinet in the primary investigator’s main place 
of employment, where it will be kept for five years.   
Data Analysis 
The primary investigator utilized Statistical Package for the Social Sciences (SPSS), 
version 22.  Data was analyzed and data sets were created with the assistance of a statistician.  
The data collected was quantitative and categorical data, therefore a t-test and paired t-tests were 
used as statistical tests as part of the data analysis.  Additionally, means, standard deviations, and 
correlations were part of the analysis.  Lastly, correlations were completed to measure 
association or relationship between BHRT and outcomes. 
Ethical Considerations 
 The study was submitted to the institutional review board (IRB) at Fresno State 
University, with permission to conduct the study granted by the Medical Director and owner of 
the private practice.  It was determined to be exempt from further IRB review due to the low 
risk nature of the study.  This was a retrospective chart review therefore health information was 
collected so anonymity was assured.  The investigator did not know or treat the majority of the 
subjects that were identified for inclusion criteria for the chart review therefore the data 
collected should have no affected bias. 
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Chapter 4 
Results 
Demographics 
 There were sixteen descriptive variables surveyed on the tool see Appendix A.   The 
mean age was 60.13 (SD = 5.02); the mean pre-treatment body weight was 156.28 pounds, and 
post treatment mean body weight of 156.27 pounds.  Table 1 presents the marital status for the 
women with the majority of patients married (78.6%).  The medications reported on initial visit 
and post Biest and Progesterone treatment is in Table 3.   
Table 1 
Marital Status (N = 101) 
Demographic n % 
  Marital Status   
Married 78 78.6% 
Divorced 8                    8.2% 
Single 7   7.1% 
Separated 3  3.1% 
Widowed 2  2.0% 
 
  The reported symptoms of menopause for the women seeking treatment during the initial 
visit are labeled in Table 2.  One patient did not list any reported symptoms therefore the table 
represents symptoms from 100 patients. The most reported symptoms were fatigue, poor sleep 
and hot flashes. 
Table 2  
Reported Symptoms at Initial Visit (N =100) 
Symptoms n % 
    Fatigue 45 45% 
    Poor Sleep 41 41% 
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    Hot Flashes/Night Sweats 35 35% 
    Weight Gain 32 32% 
    Mood Swings/PMS 29 29% 
    Low Libido 22 22% 
    Depression 20 20% 
    Brain Fog/Poor Memory 20 20% 
    Painful Intercourse/ 
    Vaginal Dryness 
 
19 
 
19% 
    Headaches/Migraines 12 12% 
    Anxiety 8 8% 
    Frequent Urination/ 
    Urinary Incontinence  
 
8 
 
8% 
 
Table 3 presents the medications by classification utilized by the women as reported 
during their initial visit and post BHRT treatment.  There were 54 women that were using 
HRT/BCP and 31 women taking thyroid medication, while post BHRT treatment the HRT/BCP 
decreased to zero and the use of thyroid medication increased to 77 women. 
Table 3  
Medications on Initial Visit and Post BHRT Treatment (N=101) 
Medications/Classifications Pre-Initial Post- Biest and Progesterone 
     n % n % 
    HRT/BCP 54 53.4% 0 0 
    Thyroid 31 30.69% 77 76.2% 
    Depression 22 21.78% 14 13.86% 
    Anti-hypertensives 20 19.8% 20 19.8% 
    GI 13 12.87% 9 8.9% 
    Allergy/Asthma 13 12.87% 11 10.89% 
    Anti-anxiety 11 10.89% 9 8.91% 
    Pain non-narcotic/migraine 11 10.89% 5 4.95% 
    Sleep aids 8 7.9% 5 4.95% 
    Pain-narcotic  6 5.94% 5 4.95% 
    Antidiabetic 4 3.96% 7 6.9% 
    Lipid lowering 4 3.96% 4 3.96% 
    Weight loss 4 3.96% 9 8.91% 
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    NSAID 4 3.96% 5 4.95% 
    ASA 4 3.96% 3 2.97% 
    Biophosphonate 3 2.97% 3 2.97% 
    Seizure 1 0.99% 1 0.99% 
    ADHD 1 0.99% 4 3.96% 
    BHRT 0 0 101 100% 
 
Table 4 identifies the total number of women with menopause induced surgeries, 
therefore the physiological decline of estrogen as a result of menopause is correlated with 
increased risk for major health variations comprising of osteoporosis, cardiovascular disease 
(CVD), and diabetes, (Nelson, 2008; Shoupe, 2012).  As presented in Table 4, total charts 
reviewed found 26 women with a surgical-induced menopause. 
Table 4  
Menopause-Induced Surgeries (N =26) 
 
Menopause-Induced Surgeries 
 
n 
 
% 
 
Partial Hysterectomy 
 
15 
 
15.15% 
 
Total Hysterectomy 
 
11 
 
11.1% 
 
Cardiac 
 Table 5 is representative of blood pressure data for the women upon initial visit and 
during the last office visit utilizing the eighth Joint National Committee guidelines (JNC 8) for 
hypertension.  The blood pressure data is limited to initial visit and last visit therefore lacking 
blood pressure data to adequately make a diagnosis of hypertension because of deficiencies of 
three consecutive blood pressure readings, lack of health history, and ethnicity according to the 
nine recommendations for instituting treatment in the JNC 8 guidelines (James et al., 2014).   
Table 5 
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Blood Pressure on Initial Visit (N = 100) and Last Visit (N = 96) 
 Initial Visit 
n =100 
Post BHRT 
n = 96 
             B/P n % n % 
          
           85 - 98 
           56 - 63 
 
3 
 
3% 
 
2 
 
1.92% 
           
         100 - 139 
           56 - 88 
 
78 
 
78% 
 
64 
 
61.44% 
 
          140 - 184 
            90 - 113 
 
19 
 
19% 
 
30 
 
28.79% 
 
The family history for cardiac incident before the age 55 was found in twenty-five 
fathers.  Forty-three of 101 (N) reported cardiac incidence of which 25 (24.8%) were fathers, 
who had known history for a cardiac event see Table 6. 
Table 6 
Family History for Cardiac Incident (N = 43) 
Family History n % 
Father 25 24.8% 
Mother 11 10.9% 
Brother 4 4.0% 
Sister 2 2.0% 
Grandfather 1 1.0% 
 
 Table 7 categorizes the type of cardiac incident experienced by the women pre-treatment 
and post BHRT treatment with compounded prescription use.  There were 23 women with a 
documented cardiac incident prior to starting treatment with Biest and Progesterone compounded 
treatment: eight of the women with a history of existing hypertension, one woman with a 
myocardial infarction, one with atrial fibrillation, one with hyperlipidemia, one woman with an 
irregular heart valve and one with mitral regurgitation see Table 7.  The existing cardiac findings 
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may perhaps lead to possible myocardial infarction. 
Table 7  
Cardiac Incidence Initial Visit and Post BHRT Treatment (N = 23) 
 
Initial Visit Cardiac Incidence 
 
n 
 
% 
Cardiac Incidence Pre   
HTN 8 18.6% 
Atrial Fib 1   2.3% 
Myocardial Infarction 1  2.3% 
Borderline HTN 1  2.3% 
HTN/Hyperlipidemia 1 2.3% 
Hyperlipidemia 1 2.3% 
Irregular Valve 1 2.3% 
Mild Mitral Regurgitation 1 2.3% 
Mitral Valve Prolapse 1 2.3% 
Phlebitis 1 2.3% 
S-Tach 1 2.3% 
Post BHRT 
Cardiac Incidence 
  
Atrial Fib 2 4.6% 
HTN 2 4.6% 
Hyperlipidemia 1 2.3% 
      Myocardial      
Infarction/Stroke 
 
0 
 
0% 
 
Descriptive Statistics 
 Table 8 represents the initial and post Progesterone dosage levels for the women ranging 
from 25 milligrams to 400 milligrams.  The 23 women initially taking 100 milligrams of 
Progesterone decreased to 15, while the women taking 200 milligrams of Progesterone was 64 
women initially and increased to 71 at the four year visit.  The most commonly used dosage of 
Progesterone was 200 milligrams in the patients. 
Table 8  
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Initial and Post Frequency and Percent of Progesterone Compounded Dosage (N=101) 
  Initial  Post 
Dose n % n % 
25-100mg 1 1.0% 0 0 
50mg 1 1.0% 1 1.0% 
50-100mg 1 1.0% 0 0 
50-200mg 4 4.0% 0 0 
100mg 23 22.8% 15 15.3% 
150mg 5 5.0% 8 8.2% 
100-200mg 1 1.0% 1 1.0% 
200mg 64 63.4% 71 72.4% 
300mg 0 0 1 1.0% 
400mg 1 1.0% 1 1.0% 
 
Screening for osteoporosis on initial visit, 40 (39.6%) women were screened for bone 
density and or c-telopeptide, while post BHRT treatment compounded prescription use, 43 
(42.5%) women were screened for bone density or c-telopeptide.  Similarly, screening for breast 
cancer, 11 (10.8%) women on initial visit had documented mammography results, while 23 
(22.7%) women post Biest and Progesterone compounded prescription patients had documented 
mammography results.  Twenty-five percent of post BHRT prescription treatment use in women 
was negative for breast cancer upon mammography screening, while the remaining patients self-
reported negative results.  Cardiac incident findings on initial visit revealed seventeen (16.8%) 
women reported had a previous cardiac history while, five (4.9%) women post BHRT 
compounded prescription use had reported a cardiac incident, and no myocardial infarctions 
were reported refer to Table 7. 
The Biest medication route of preferred administration method on initial visit and post 
last visit is detailed in Table 9, with 88 women on initial visit that were prescribed a gel based 
Biest.  Subsequently on the last visit the Biest method of administration increased to 90 women, 
while cream was not as commonly utilized. 
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Table 9 
Initial and Post Method of Biest Administration (N = 101) 
 Initial Post 
Method n % n % 
Cream 12 11.9% 7 6.9% 
Gel 88 87.1% 90 89.1% 
Gel / Cream 1  1.0% 4 4.0% 
 
Inferential Statistics 
 A paired samples t-test was conducted to determine the difference between pre BHRT 
and post BHRT for bone density.  There were 29 patients with bone density data collected both 
prior to treatment and post BHRT treatment, a paired samples t-test indicated no significant 
difference between previous to BHRT treatment on bone density (M = 403.55, SD = 236.14) and 
post BHRT treatment bone density levels (M = 367.10, SD = 191.74) see Table 10. 
Table 10 
Mean, Standard Deviation, and Standard Error for Bone Density (N = 29) 
            Bone Density M SD SE 
Previous to BHRT 403.55 236.14 43.85 
Post-test BHRT 367.10 191.74 35.61 
 
Bone density did not significantly decrease after treatment, while there was a significant 
correlation between pre BHRT and post BHRT treatment and bone density: r(29) = .568, p = 
.001 as shown in Table 11. 
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Table 11 
Paired Samples t-test Comparison of Pre and Post BHRT Treatment on Bone Density  
(N = 29) 
 Dif. Of Means SD r t df Sig. (2-tailed) 
Pre – Post  36.45 198.70 .586 .988 28 .332 
 
 A paired samples t-test was conducted to determine the difference between pre BHRT 
and post BHRT treatment use on total cholesterol.  For the 58 patients where total cholesterol 
data was collected both pre and post compounded prescription of BHRT treatment use, a paired 
samples t-test indicated no significant difference between pre Biest and Progesterone total 
cholesterol (M = 205.26, SD = 40.00) and post BHRT prescription use on total cholesterol (M = 
201.19, SD = 34.74), t(57) = .808, p = .422  refer to Table 12. 
Table 12 
Mean, Standard Deviation, and Standard Error for Total Cholesterol (N = 58) 
Total Cholesterol M SD SE 
Previous to BHRT 205.26 40.00 5.25 
Post test  201.19 34.74 4.56 
 
Total cholesterol levels did not significantly decrease after treatment.  There was a 
significant correlation between pre Biest and Progesterone and post BHRT medication use on 
total cholesterol: r(58) = .481, p < .001 see Table 13. 
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Table 13 
Paired Samples t-test Comparison of Pre and Post BHRT Treatment on Total Cholesterol 
(N = 58) 
 Dif. Of Means SD r t df Sig. (2-tailed) 
Pre – Post 4.07 38.34 .481 .808 57 .442 
 
A paired samples t-test was conducted to determine the difference between pre BHRT 
and post BHRT prescription use on HDL cholesterol.  For the 57 patients where HDL cholesterol 
data was collected both pre BHRT and post prescription of BHRT, a paired samples t-test 
indicated no significant difference between pre BHRT on HDL levels (M = 67.33, SD = 20.25) 
and post BHRT on HDL cholesterol levels (M = 68.70, SD = 18.46), t(56) = -.777, p = .441 see 
Table 14.   
Table 14 
Mean, Standard Deviation, and Standard Error for HDL Cholesterol (N = 57) 
HDL Cholesterol M SD SE 
Previous to BHRT  67.33 20.25 2.68 
Post test 68.70 18.46 2.44 
 
HDL cholesterol levels did not significantly increase after treatment.  There was a 
significant correlation between pre BHRT prescription use and post BHRT prescription use on 
HDL cholesterol: r(57) = .768, p < .001 see Table 15. 
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Table 15 
Paired Samples t-test Comparison of Pre and Post BHRT Treatment on HDL cholesterol 
(N = 57) 
 Dif. Of Means SD r t df Sig. (2-tailed) 
Pre – Post -1.37 13.30 .768 -.777 56 .441 
 
 A paired samples t-test was conducted to determine the difference between pre BHRT  
and post BHRT on LDL cholesterol levels.  For the 58 patients where LDL cholesterol data was 
collected both pre and post compounded prescription of BHRT, a paired samples t-test indicated 
no significant difference between pre BHRT LDL cholesterol levels (M = 116.83, SD = 33.64) 
and post BHRT on LDL cholesterol levels (M = 113.88, SD = 29.73), t(57) = .653, p = .517 refer 
to Table 16.   
Table 16 
Mean, Standard Deviation, and Standard Error for LDL Cholesterol (N = 58) 
LDL Cholesterol M SD SE 
Pre test 116.83 33.64 4.42 
Post test 113.88 29.73 3.90 
 
LDL cholesterol levels did not significantly decrease after treatment.  There was a 
significant correlation between pre BHRT and post BHRT levels of LDL cholesterol: r(58) = 
.416, p = .001 see Table 17. 
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Table 17 
Paired Samples t-test Comparison of Pre and Post BHRT on LDL cholesterol (N = 58) 
 Dif. Of Means SD r t df Sig. (2-tailed) 
Pre – Post 2.95 34.41 .416 .653 57 .517 
 
A paired samples t-test was conducted to determine the difference between pre Biest and 
Progesterone and post BHRT on Triglyceride levels.  The 57 patients with Triglyceride data was 
collected both pre and post compounded prescription use of BHRT, a paired samples t-test 
indicated no significant difference between pre Biest and Progesterone Triglyceride levels (M = 
105.93, SD = 59.71) and post BHRT Triglyceride levels (M = 97.42, SD = 44.93), t(56) = 1.517, 
p = .135 seen in Table 18.   
Table 18 
Mean, Standard Deviation, and Standard Error for Triglyceride (N = 57) 
Triglyceride M SD SE 
Previous to BHRT test 105.93 59.74 7.91 
Post test 94.42 44.93 5.95 
 
Triglyceride levels did not significantly decrease after treatment.  There was a significant 
correlation between pre Biest and Progesterone and post BHRT levels of Triglyceride: r(57) = 
.707,  p < .001 see Table 19. 
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Table 19 
Paired Samples t-test Comparison of Pre and Post BHRT on Triglyceride Levels  
(N = 57) 
 Dif. Of Means SD r t df Sig. (2-tailed) 
Pre – Post 8.51 42.34 .707 1.517 56 .135 
 
An independent samples t-test was conducted to determine the difference on triglycerides 
level between Biest dosage after four years of compounded prescription use.  Using the equality 
of variances correction, an independent samples t-test indicated a significant difference between 
triglyceride level between two/two compounded prescription dosage (M = 73.13, SD = 19.35) 
and two/four compounded prescription dosage (M = 113.52, SD = 53.03), t(35) = -3.221, p = 
.003 see Table 20. 
Table 20 
Mean, Standard Deviation, and Standard Error for Triglyceride Level (N = 37) 
Dose n M SD SE 
Two/Two 16 73.13 19.35 4.84 
Two/Four 21 113.52 53.03 11.57 
 
An independent samples t-test was conducted to determine the difference on HDL 
cholesterol level between progesterone dosages after four years of prescription use.  An 
independent samples t-test indicated a significant difference between HDL cholesterol level 
between 100 milligrams prescription (M = 101.75, SD = 28.86) and 200 milligrams prescription 
(M = 67.20, SD = 17.99), t(48) = 3.517, p = .001  refer to Table 21. 
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Table 21 
Mean, Standard Deviation, and Standard Error for HDL Cholesterol Level (N = 50) 
Dose n M SD SE 
100 milligrams 4 101.75 28.86 14.43 
200 milligrams 46 67.20 17.99 2.65 
 
 A Pearson correlation was conducted to determine the relationship between pre 
progesterone level, post progesterone level, weight, age, post total cholesterol, post HDL 
cholesterol, and post LDL cholesterol.  There was a significant negative relationship between 
post progesterone dosage and post HDL cholesterol levels: r(58) = -.289, p = .028, r
2
 = .08, as 
progesterone level increased, post HDL cholesterol decreased. 
There was no significant difference between post routes of administration (cream or gel) 
for post total cholesterol; post HDL, post LDL, post triglyceride, post bone density, age, or 
weight.  Additionally there was no other significance between dose on post total cholesterol, post 
LDL, post triglyceride, post bone density, age, or weight.  There were significant correlations 
noted for the paired samples t test; the only other significant correlation was post progesterone 
level and post HDL cholesterol. 
Chapter 5 
Discussion 
A retrospective chart review was conducted on 101 charts from a Southern California 
private practice.  All women who had utilized Biest and Progesterone for four or more years 
were included.  The purpose of the project was to evaluate retrospectively if Biest and 
Progesterone compounded prescription use in women after four or more years increased the risk 
for osteoporosis, breast cancer and cardiovascular disease.  The population was predominately 
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Caucasian and married.  Their body weight stayed consistent with pre-treatment and post-
treatment regimen.  Only one patient reported no initial symptoms before seeking bioidentical 
hormone replacement treatment, while the remainder of the women disclosed symptoms of 
fatigue, poor sleep, hot flashes, and weight gain. Additional symptoms reported, but not as 
significant, included: depression, painful intercourse, brain fog, anxiety, frequent 
urination/urinary incontinence, hair thinning, and migraine/headaches.   
Of the 101 women, 31 utilized thyroid medications and 54 women used birth control or 
hormone replacement therapy prior to being prescribed Biest and Progesterone.  There were 20 
women taking antihypertensive agents, four on antidiabetic medications, and four utilizing lipid- 
lowering agents, therefore past medical history would have revealed valuable information about 
the population.   
The blood pressure on initial visit found 19 women were in the hypertensive category 
utilizing the Eighth Joint National Committee Guidelines, while at the four year mark there were 
30 women whose blood pressure was in the 140/90 – 184/113 hypertensive category. Frequently 
used medications included: non-steroidal anti-inflammatory, narcotic pain and non-narcotic pain 
medications.  While less commonly used medications were: allergy asthma medications and 
biophsphonates  prior to Biest and Progesterone compounded prescription use.  The use of sleep 
medications was found in eight patient charts: 11 women were utilizing anti-anxiety medication 
one patient was on a seizure medication, five women were utilizing antivirals, two were 
receiving treatment with antifungals, three patients were being treated with antibiotics and one 
patient was being treated with an attention deficit hyperactivity disorder medication.  The patient 
population seen in the practice may also be receiving medical treatment for chronic fatigue, 
fibromyalgia, autoimmune illnesses and or Lyme disease, in addition to bioidentical hormone 
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replacement therapy.  
Family history of cardiac incidence before the age of 55 was identified in fathers more 
frequently than in other family members, and mothers were the second most commonly found.  
One patient of the 101 reviewed charts reported cardiac incidence for myocardial infarction prior 
to Biest and Progeserone compounded prescription use, while one patient experienced sinus 
tachycardia, one reported history of phlebitis, and one had documented mild mitral regurgitation.  
There were no reported cardiac incidences for myocardial infarction or stroke post Biest and 
Progesterone compounded use, however, two patients had reported new onset of atrial 
fibrillation; two experienced hypertension, and one developed hyperlipidemia. 
The initial Progesterone dose in the 101 charts reviewed was 100 mg in 23 (22.8%) 
patients and 200 mg in 64 (63.4%) of the women, while 200 mg post Progesterone dosage 
increased to 71 (72.4%) women and the 100 mg dosage of Progesterone decreased to 15 (15.3%) 
women.  There was one (1%) patient taking 50 mg and one (1%) utilizing 400 mg of 
Progesterone after four years of use.  Of the Biest prescription use, 88 (87.1%) women applied a 
gel based compounded prescription, 12 (11.9%) utilized a cream based compounded 
prescription, and one (1.0%) used a combination of gel and cream compounded prescription. 
Forty patients out of the 101 were screened for bone density while post Biest and 
Progesterone compounded prescription use there were 43 patients screened for bone density and 
or C-telopeptide markers, with no change in findings for increase in osteoporosis from initial 
visit to last visit.  The lack of mammography and bone density results may be due to the fact that 
most of these patients had mammograms or bone density outside of this practice and test results 
were not regularly forwarded to the medical facility.   
Total cholesterol levels were analyzed in 58 of the 101 women after at least four years of 
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use with Biest and Progesterone compounded prescription.  Initial analysis using a paired sample 
t-test revealed no significant difference between pre prescription Biest and Progesterone use and 
post BHRT on total cholesterol levels however, there was a significant correlation seen between 
pre Biest and Progeserone and post BHRT use on total cholesterol levels.  The results revealed a 
decrease in total cholesterol with a mean difference of 4.07 and the Pearson coefficient r(58) 
=.481, p < .001 see Table 11. 
A paired samples t-test was conducted on low density lipoprotein levels (LDL), in pre 
Biest and Progesterone compounded prescription use revealing a Mean of 116.83 and a Standard 
Deviation of 33.64, while the difference between post Biest and Progesterone compounded 
prescription use on LDL levels revealed a mean of 113.88, and a standard deviation of 29.73.  
No significant difference was found in LDL cholesterol.  A Pearson correlation was conducted 
between pre BHRT prescription use and post BHRT treatment on LDL cholesterol levels and 
there was a significant correlation: r(58) = .416, and p=.001 refer to Table 13. 
Summary 
 This project has expanded research of bioidentical hormone replacement therapy with 
Biest and Progesterone compounded prescription used for four years or more, with outcomes 
related to patient safety by evaluating a population of women for breast cancer incidence, cardiac 
incidence and assessment for bone loss.  The focus was to evaluate the use of Biest and 
Progesterone after a period of time for safety and to identify the effects specific to bone loss, 
cholesterol levels, cardiac incidence and breast cancer incidence.  The results yielded valuable 
information regarding the impact of Biest and Progesterone on total cholesterol levels, 
triglycerides, LDL, and HDL levels.  There were a few women on lipid-lowering medications on 
initial visit and this may have a slight impact on the cholesterol results for this study. 
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 The use of Biest and Progesterone compounded prescription treatment for four years or 
more revealed no breast cancer incidence with the women in the study, however only 25% had 
mammography reports available while the remaining had self-reported results for negative 
incidence.  Cardiac incidence revealed no reported MI occurred within this population, and 
cholesterol profiles remained relatively unchanged from the start of treatment to after four years 
with the exception of a slight decrease in HDL levels.  Future studies should include randomized 
controlled trials that would continue to evaluate women for breast cancer incidence while 
utilizing Biest and Progesterone therapy.  Mammography results would be prudent to have 
available in future studies.  Lastly, future studies should include the use of testosterone 
replacement therapy concurrently with Biest and Progesterone compounded prescription use in 
menopausal women. 
Limitations 
There were a number of limitations identified in this study.  One limitation included the 
tool that had not been previously piloted therefore the validity and reliability of the tool had not 
been tested.   Future projects should include a past medical history, specifically for breast cancer, 
smoking history, exercise and diet.  There was also a lack of identification of the population 
specific to ethnicity within the patient information no question existed within the initial office 
visit patient questionnaire.  The blood pressures obtained from the women in the study did not 
include sufficient information to make any conclusions regarding the incidence for hypertension 
with the prescribed BHRT treatment.  Only one blood pressure was obtained from the initial visit 
and subsequently one from the last visit and three consecutive blood pressures are required to 
diagnose hypertension according to the JNC 8 guidelines for hypertension (James, et al., 2014). 
 The practice required payment at the time services were rendered and was an out-of-
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network practice.   Patients are unable to apply insurance coverage at the time of their visits, 
resulting in a financial limitation for some patients.  The changes in health care has led to 
concierge medicine which began in 1996, when Dr. Howard Maron, a Seattle Supersonics 
basketball team doctor, and Dr. Scott Hall decided to offer the  same opportunity for luxury care 
to a selected group of patients (DiGiacomo, 2006).  This type of medical care is also referred to 
as retainer, boutique, luxury primary care, or luxury medicine (Jones & Treiber, 2010).  
Therefore, the patient population could be considered to be of middle to upper class however no 
financial information was available about the population.  Additionally, this was a retrospective 
chart review and this was information from one office and not a randomized control study which 
is the gold standard in research design because it contains the highest level of validity (West, et 
al., 2008).  Another limitation is the lack of available treatment with bioidentical hormone 
replacement therapy in mainstream medicine because of the controversies and lack of evidence-
based support from the Endocrine Society and the American College of Obstetricians and 
Gynecologists for the use of this treatment for the relief of menopausal symptoms. 
Bias 
The one bias was patients were selected from an in-office Compounding Four System, 
excluding patients who obtained their prescriptions from other compounding pharmacies.   
Implications for Nursing Practice 
There is a lack of evidence-based studies in the medical and advanced practice nursing literature 
that support the treatment of patients with peri-menopause and menopause symptoms with the 
use of bioidentical compounded Biest and Progesterone therapy.  Throughout the course of 
researching the literature for this project, there were limited studies which evaluated any 
bioidentical hormone usage for over a year of continuous use.  Since the publication of the 
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Women’s Health Initiative (2002), results women are seeking alternative treatment with 
bioidentical hormones and the safety of these hormones has not been established according to the 
literature (Cirigiliano, 2007; Ruiz et al., 2011). 
. 
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Appendix A 
                                         
                                 CHART REVIEW TOOL                      Page 1 
          Assessment Information         Assessment Findings 
De-identified Number Assigned  
 
1 
 
Initial Visit Age  
Age Initial visit                 Age Last visit 
 
2 
 
Marital Status 
 
Single                                       
 
Married
 
Divorced   
 
Separated                      
 
Widowed 
 
3 
  
Symptoms @ Initial Visit 
 
 
 
 
 
4 
 
Weight @ initial & last visit 
Initial  Last 
 
5 
 
Menopause induced surgeries    
No                                   Yes 
Total hysterectomy Date:                    
Partial hysterectomy Date: 
 
6 
 
Current Medications being used 
1. 
2. 
3. 
4.                                      
5. 
6. 
7.  
6a Medications used on during last visit 1. 
2. 
3. 
4. 
5. 
6. 
7. 
 
7 
 
Date initiating BHRT (prescribed) 
 
Month 
 
Year 
 
8 
 
BHRT dosage of Progesterone & if cycles 
                                  
Dosage                         
 
Yes Cycles                   
No Cycling      Days of cycling 
8a BHRT dosage of Progesterone & if cycles Dosage 
   
Yes Cycles                   
 
No Cycling 
 
Days of cycling 
9 BHRT route of Progesterone prescribed Oral    Gel                                       Cream
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10 
 
  
BHRT dosage of Biest  
Initial Change 
 
10a 
 
BHRT route of Biest prescribed 
Topical                  Cream 
Gel 
Vaginal                   Oral                Drops           
Sublingual 
 
11 
 
BHRT dosage of Biest (current) 
 
 
 
11a 
 
BHRT route of Biest prescribed 
Topical            Cream 
Gel                      
Vaginal               Oral                  Drops 
Sublingual 
 
12 
 
Bone density or CTX documented 
 
Yes 
 
No 
 
Results: 
 
13 
 
Bone density or CTX documented post 
BHRT 
Yes                                              Results: 
No 
 
14 
Mammography results prior to BHRT 
documented 
 
Yes                   
 
No 
 
15 
 
Mammography results/documented post 
BHRT what year  
Yes                                             No Year
      
Results 
negative        
Results positive 
 
17 
 
B/P initial Visit 
 
B/P 
 
17a 
 
B/P last Visit 
 
B/P 
 
18 
 
Family history for cardiac disease 
Mother, father, brother, sister before 55 
years of age 
 
Yes 
 
No   
 
Condition:  
 
Family member:  Mother_____ Father______    
Brother_______   Sister______ 
 
19 
 
Cardiac incidence prior to BHRT 
 
 
No                                              
 
Yes
 
Condition:
 
19a 
 
Cardiac incidence since BHRT 
 
No 
 
Yes 
 
Condition: 
 
 
20 
 
Cholesterol screening Initial 
Yes 
 
No Total 
Chol  
 
 
HDL LDL TRI 
Date 
Results 
 
20a 
Cholesterol screening following BHRT 
                    
Date Results_______________ 
Yes                          No Total 
Chol           
HDL       LDL TRI 
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Appendix B 
 
                                       CENTERS FOR HORMONE IMBALANCE, HYPOTHYROIDISM AND FATIGUE 
 
September 24, 2014 
 
To: California State University, Fresno Committee of the Protection of Human Subjects 
 
Re: Maria D. White's Doctor of Nursing Practice Project 
 
I, Kent Holtorf M.D., medical director and owner of the Holtorf Medical Group am writing this 
letter as verification of full support for Maria White's BHRT retrospective study.  I am therefore 
confirming by this written letter no Institutional Review Board (IRB) approval within this 
office setting is required. The office is located at 23456 Hawthorne Blvd Torrance, CA and I 
can be reached at 310-375-2705, if you have any further questions. 
 
 
 
 
 
 
 
 
BIOIDENTICAL HORMONE SAFETY  67 
 
Appendix C 
California State University,  
Fresno School of Nursing  
IRB Approval 
 
 
 
 
 
Date:  November 14, 2014 
 
RE: DNP1423 – Bio identical Hormones Utilized for Treating Menopausal Symptoms: Are They 
Safe? 
 
Dear Maria White,  
 
As the Chair of the Department of Nursing Research Committee, serving as the Institutional Review 
Board for the Department of Nursing, I have reviewed and approved your review request for the above-
referenced project for a period of 12 months. I have determined your study to meet the criteria for 
EXEMPT IRB review.  
 
Under the Policy and Procedures for Research with Human Subjects at California State University, 
Fresno, your proposal meets exempt criteria according to section 
 
3.5.2.C: Research involving the collection or study of existing data, documents, records, pathological specimens or diagnostic 
specimens, if these sources are routinely available to the investigator, and are recorded by the investigator in such a manner 
that makes identification of the subjects impossible.  
 
The Research Committee may periodically wish to assess the adequacy of research process.  
If, in the course of the study, you consider making any changes in the protocol or consent form, you 
must forward this information to the Research Committee prior to implementation unless the change is 
necessary to eliminate an apparent immediate hazard to the research participant(s).  
 
This study expires: November 14, 2015 
 
The Research Committee is authorized to periodically assess the adequacy of the consent and research 
process. All problems having to do with subject safety must be reported to the Research Committee. 
Please maintain proper data control and confidentiality.  
 
If you have any questions, please contact me through the CSU, Fresno School of Nursing Research 
Committee at tereag@csufresno.edu.  
 
Sincerely,  
 
Terea Giannetta, DNP 
Department of Nursing, Research Committee, Chair 
 
